Post Doctoral Training Fellow - Homologous Recombination Defective Cancers - Prof C Lord (ID 567)

Key Information

Salary: £34,344 - £44,034 dependent on relevant Postdoctoral experience. Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at  £34,344 until the successful completion of their viva. 

This role is eligible for ICR Sponsorship.  Support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here. 

Duration of Contract: Fixed Term till 30 September 2027 

Hours per week: 35 hours per week (Full Time)

Job Details 

Under the leadership of Professor Chris Lord, we are seeking to appoint a creative and motivated Post Doctoral Training Fellow to study synthetic lethal interactions involving homologous recombination defective cancers.  

The proposed project aims to experimentally characterise how resistance to PARP inhibitors used in the treatment of the disease occurs and to devise ways of either preventing or delaying the emergence of resistant tumour clones.

Key Requirements

The successful candidate must have a PhD in biology, genetics or other associated subjects together with considerable experience in cell and molecular biology, tissue culture and with genome editing technologies (e.g. CRISPR-Cas-9).   

The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up  to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years

Department/Directorate Information:

The Gene Function Laboratory, led by Prof. Chris Lord, focuses upon identifying and understanding tumour specific dependencies, such as synthetic lethal effects, as a means to design novel approaches to treating cancer. We have made major advances in identifying synthetic lethal interactions involving, for example, PARP inhibitors (Farmer et al Nature 2005, Edwards et al Nature 2008, Pettitt et al Cancer Discovery 2020, Krastev et al Nature Cell Biol 2022), ATR inhibitors (Williamson et al, Nature Communications 2016), Polq inhibitors (Zatreanu et al Nature Comms 2021) and ROS1 inhibitors (Bajrami et al Cancer Discovery (2018).

The Breast Cancer Now Toby Robins Research Centre at the ICR is the first centre in the UK entirely devoted to breast cancer research. Our goal is to advance research into the causes, diagnosis and treatment of breast cancer. It is located in state-of-the-art laboratory space, with excellent core facilities.

We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr Stephen Pettitt via email, stephen.pettitt@icr.ac.uk

About The Institute of Cancer Research

Why work for us?

As a member of staff, you'll have exclusive access to a range of staff benefits.

The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here. 

We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.